Regen BioPharma Inc. Files 10-Q for Period Ending December 31, 2023

TL;DR

<b>Regen BioPharma Inc. has filed its quarterly report (10-Q) for the period ending December 31, 2023, detailing its financial status and operations.</b>

AI Summary

Regen BioPharma Inc (RGBPP) filed a Quarterly Report (10-Q) with the SEC on January 19, 2024. Regen BioPharma Inc. filed a 10-Q report for the period ending December 31, 2023. The filing covers the first quarter of fiscal year 2024. The company's fiscal year ends on September 30. Regen BioPharma Inc. is incorporated in Nevada. The company's business and mailing address is located in La Mesa, California.

Why It Matters

For investors and stakeholders tracking Regen BioPharma Inc, this filing contains several important signals. This filing provides investors with an update on the company's financial performance and operational status for the most recent quarter. Understanding the details within this 10-Q is crucial for assessing Regen BioPharma's current financial health and future prospects.

Risk Assessment

Risk Level: low — Regen BioPharma Inc shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not contain immediate, significant financial or operational disclosures that would alter the risk profile.

Analyst Insight

Review the detailed financial statements and management discussion within the 10-Q to understand Regen BioPharma's performance and outlook.

Key Numbers

• 2023-12-31 — Period End Date (The 10-Q filing is for the period ending December 31, 2023.)
• 2024-01-19 — Filing Date (The 10-Q was filed on January 19, 2024.)
• 0930 — Fiscal Year End (Regen BioPharma Inc.'s fiscal year ends on September 30.)

Key Players & Entities

• Regen BioPharma Inc. (company) — Filer of the 10-Q report.
• 2023-12-31 (date) — End of the reporting period for the 10-Q.
• 2024-01-19 (date) — Filing date of the 10-Q.
• La Mesa, CA (location) — Location of Regen BioPharma Inc.'s business and mailing address.
• NV (location) — State of incorporation for Regen BioPharma Inc.

Forward-Looking Statements

• Regen BioPharma Inc. will continue to report no significant revenue in its next quarterly filing. (Regen BioPharma Inc.) — high confidence, target: Q2 2024
• The company will likely need to raise additional capital to fund operations given its pre-revenue status. (Regen BioPharma Inc.) — medium confidence, target: next 12 months

FAQ

Industry Context

Regen BioPharma Inc. operates within the pharmaceutical preparations industry.

Regulatory Implications

The filing is made in accordance with the Securities Exchange Act of 1934.

What Investors Should Do

1. Analyze the balance sheet, income statement, and cash flow statement for the quarter ended December 31, 2023.
2. Review any disclosures related to ongoing clinical trials or research and development activities.
3. Compare the financial results to the same period in the prior year to identify trends.

Year-Over-Year Comparison

This is the first 10-Q filing for the fiscal year ending September 30, 2024, providing an update from previous filings.

Filing Documents

• rgbp123123form10q.htm (10-Q) — 829KB
• ex31_1.htm (EX-31.1) — 9KB
• ex31_2.htm (EX-31.2) — 9KB
• ex32_1.htm (EX-32.1) — 4KB
• ex32_2.htm (EX-32.2) — 4KB
• 0001607062-24-000033.txt (&nbsp;) — 3618KB
• rgbp-20231231.xsd (EX-101.SCH) — 38KB
• rgbp-20231231_cal.xml (EX-101.CAL) — 42KB
• rgbp-20231231_def.xml (EX-101.DEF) — 135KB
• rgbp-20231231_lab.xml (EX-101.LAB) — 214KB
• rgbp-20231231_pre.xml (EX-101.PRE) — 191KB
• rgbp123123form10q_htm.xml (XML) — 405KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File No. 333-191725 REGEN BIOPHARMA INC (Exact name of small business issuer as specified in its charter) Nevada 45-5192997 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4700 Spring Street , St 304 , La Mesa , California 91942 (Address of Principal Executive Offices) 619 722-5505 (Issuer's telephone number) None (Former name, address and fiscal year, if changed since last report) Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "non-accelerated Large accelerated filer Accelerated Smaller reporting company Emerging Growth Company APPLICABLE ONLY TO CORPORATE ISSUERS: As of December 31, 2023 Regen Biopharma, Inc. had 3,750,565 common shares outstanding. As of December 31, 2023 Regen Biopharma, Inc. had 409,551 shares of Series A Preferred Stock outstanding. As of December 31, 2023 Regen Biopharma, Inc. had 34 shares of Series AA Preferred Stock outstanding. As of December 31, 2023 Regen Biopharma, Inc. had 29,338 shares of Series M Preferred Stock outstanding. As of December 31, 2023 Regen Biopharma, Inc. had 15,007 shares of Series NC Preferred Stock outstanding Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes No 1 PART I - FINANCIAL INFORMATION Item 1. - Financial Statements REGEN BIOPHARMA , INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of December 31, 2023 September 30, 2023 (unaudited) ASSETS CURRENT ASSETS Cash $ 124,497 $ 121,037 Accounts Receivable, Related Party 12,298 0 Note Receivable, Related Party 0 Prepaid Expenses 0 Prepaid Rent 5,000 10,000 Total Current Assets 141,795 131,037 OTHER ASSETS Investment Securities, Related Party 17,733 222,580 Total Other Assets 17,733 222,580 TOTAL ASSETS $ 159,528 $ 353,617 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable 44,183 29,674 Notes Payable 49,210 95,710 Accrued payroll taxes 4,241 4,241 Accrued Interest 360,353 342,588 Accrued Payroll 1,256,630 1,256,630 Other Accrued Expenses 41,423 41,423 Bank Overdraft 1,000 1,000 Due to Investor 20,000 20,000 Unearned Income 1,560,091 1,591,731 Unearned Income ( Related Party) 0 15,126 Derivative Liability 1,400,000 1,400,000 Convertible Notes Payable Less unamortized discount 499,880 499,880 Convertible Notes Payable, Related Parties Less unamortized discount 10,000 10,000 Total Current Liabilities 5,247,010 5,308,003 Long Term Liabilities: Convertible Notes Payable, Related Parties Less unamortized discount — Notes Payable 153,981 149,614 Total Long Term Liabilities 153,981 149,614 Total Liabilities 5,400,991 5,457,617 STOCKHOLDERS' EQUITY (DEFICIT) Common Stock ($ .0001 par value); 5,800,000 shares authorized and 3,750,565 issued and outstanding as of December 31, 2023 and 3,506,366 shares issued and outstanding as of September 30,2023. 376 352 Preferred Stock, 0.0001 par value, 800,000,000 authorized as of December 31, 2023 and September 30, 2023 respectively — Series A Preferred; 739,000,000 authorized as of September 30, 2023 and December 31,2023 409,551 outstanding as of December 31, 2023 and September 30, 2023 40 40 Series AA Preferred; $ 0.0001 par value 600,000 authorized and 34 and 34 outstanding as of December 31, 2023 and September 30,2023 respectively 0 0 Series M Preferred; $ 0.0001 par value 60,000,000 authorized and 29,338 outstanding as of September 30, 2023 and 60,000,000 authorized and 29,338 outstanding as of December 31, 2023 3 3

View Full Filing

View this 10-Q filing on SEC EDGAR